<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Objective:  Le Fort III osteotomy with distraction osteogenesis (DO) is used to improve the retruded midface in patients with <z:e sem="disease" ids="C0010273" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Crouzon</z:e> or <z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Apert syndrome</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>This study aimed to evaluate sagittal and vertical preoperative and postoperative cephalometric changes of DO of the midface in patients with <z:e sem="disease" ids="C0010273" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Crouzon</z:e> or <z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Apert syndrome</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Design:  Population-based case-control study </plain></SENT>
<SENT sid="3" pm="."><plain>Patients and Methods:  Records of patients with the syndrome of <z:e sem="disease" ids="C0010273" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Crouzon</z:e> (N = 6) or <z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Apert</z:e> (N = 7) were compared, before and after Le Fort III DO, with a nonsyndromic untreated control group (N = 486) </plain></SENT>
<SENT sid="4" pm="."><plain>Main Outcome Measures:  Sagittal and vertical cephalometric maxillary landmarks and measurements were used to predict and measure midface advancement and rotation after Le Fort III DO </plain></SENT>
<SENT sid="5" pm="."><plain>Cephalograms were taken before surgery (T0), 4 months after surgery at removal of the distraction device (T1), and 1 year after removal of the distraction device (T2) </plain></SENT>
<SENT sid="6" pm="."><plain>Analysis:  Z scores were performed to compare cephalometric measures of syndromic patients with control subjects </plain></SENT>
<SENT sid="7" pm="."><plain>Results:  Cephalograms of 13 patients with the syndrome of <z:e sem="disease" ids="C0010273" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Crouzon</z:e> (N = 6) or <z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Apert</z:e> (N = 7) (age range 8.2 to 19.8 years) were evaluated </plain></SENT>
<SENT sid="8" pm="."><plain>Treatment changes (T1-T2) showed statistically significant maxillary advancement, with no significant differences between the patients with the syndrome of <z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Apert</z:e> or <z:e sem="disease" ids="C0010273" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Crouzon</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Conclusions:  DO of the midface in patients with the syndrome of <z:e sem="disease" ids="C0010273" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Crouzon</z:e> and <z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Apert</z:e> seems to be stable in the sagittal direction after follow-up </plain></SENT>
<SENT sid="10" pm="."><plain>Although <z:e sem="disease" ids="C0010273" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Crouzon</z:e> and <z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Apert</z:e> differ after DO, anteroposterior craniofacial dimensions were significantly improved and were closer to patterns of <z:mpath ids='MPATH_458'>normal</z:mpath> subjects </plain></SENT>
</text></document>